Is PSCBF or VYM a better dividend investment in 2026?

PSCBF currently yields 1818.18% with a 5% 5-year dividend growth rate. VYM yields 2.41% with 7.8% growth. The better choice depends on your goal: PSCBF offers higher current income.

What is the dividend yield difference between PSCBF and VYM?

PSCBF has a forward dividend yield of 1818.18% ($2.00/share annually). VYM yields 2.41% ($3.51/share annually). The yield gap is 1815.77 percentage points.

Home › Compare › PSCBF vs VYM

PSCBF vs VYM: Dividend Comparison 2026

PSCBF yields 1818.18% · VYM yields 2.41%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PSCBF wins by $4103414683.81M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PSCBF

● Live price

1818.18%

Share price

$0.11

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4103414683.84M

Annual income

$3,702,796,788,756,407.00

Full PSCBF calculator →

VYM

Vanguard High Dividend Yield ETF

● Live price

2.41%

Share price

$145.48

Annual div

$3.51

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$27.8K

Annual income

$278.55

Full VYM calculator →

Portfolio growth — PSCBF vs VYM

📍 PSCBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PSCBF	VYM
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PSCBF + VYM cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PSCBF pays

VYM pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSCBF

Annual income on $10K today (after 15% tax)

$154,545.45/yr

After 10yr DRIP, annual income (after tax)

$3,147,377,270,442,946.00/yr

VYM

Annual income on $10K today (after 15% tax)

$205.23/yr

After 10yr DRIP, annual income (after tax)

$236.77/yr

At 15% tax rate, PSCBF beats the other by $3,147,377,270,442,709.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSCBF + VYM for your $10,000?

PSCBF: 50%VYM: 50%

100% VYM50/50100% PSCBF

Portfolio after 10yr

$2051707341.93M

Annual income

$1,851,398,394,378,342.80/yr

Blended yield

90.24%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSCBF buys

VYM buys

No recent congressional trades found for PSCBF or VYM in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPSCBFVYM

Forward yield	1818.18% ✓	2.41%
Annual dividend / share	$2.00	$3.51 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4103414683.84M ✓	$27.8K
Annual income after 10y	$3,702,796,788,756,407.00 ✓	$278.55
Total dividends collected	$4074760433.31M ✓	$2.6K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: PSCBF vs VYM ($10,000, DRIP)

Year	PSCBF Portfolio	PSCBF Income/yr	VYM Portfolio	VYM Income/yr	Gap
1← crossover	$192,518	$181,818.18	$11,151	$241.44	+$181.4K → PSCBF
2	$3,477,331	$3,271,336.99	$12,413	$246.79	+$3.46M → PSCBF
3	$58,943,217	$55,222,471.89	$13,794	$251.79	+$58.93M → PSCBF
4	$937,891,469	$874,822,227.57	$15,306	$256.47	+$937.88M → PSCBF
5	$14,012,869,532	$13,009,325,660.38	$16,960	$260.84	+$14012.85M → PSCBF
6	$196,647,994,247	$181,654,223,846.76	$18,768	$264.92	+$196647.98M → PSCBF
7	$2,592,865,386,485	$2,382,452,032,641.56	$20,745	$268.71	+$2592865.37M → PSCBF
8	$32,132,661,421,271	$29,358,295,457,731.54	$22,905	$272.24	+$32132661.40M → PSCBF
9	$374,409,247,740,494	$340,027,300,019,734.44	$25,265	$275.51	+$374409247.72M → PSCBF
10	$4,103,414,683,838,736	$3,702,796,788,756,407.00	$27,842	$278.55	+$4103414683.81M → PSCBF

PSCBF vs VYM: Complete Analysis 2026

PSCBF — Stock

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Full PSCBF Calculator →

VYM — ETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →

📬

Get this PSCBF vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSCBF vs SCHD PSCBF vs JEPI PSCBF vs O PSCBF vs KO PSCBF vs MAIN PSCBF vs VIG PSCBF vs DGRO PSCBF vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.